UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of: May, 2004
Commission File Number: 000-50393
NEUROCHEM INC.
7220 Frederick-Banting, Suite 100
Saint-Laurent, Quebec
H4S 2A1
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
May 11, 2004
By: /s/ David Skinner
----------------------------------------
David Skinner
Director, Legal Affairs,
General Counsel and Corporate Secretary
NEUROCHEM INC.
275 Armand-Frappier Blvd
[LOGO "NEUROCHEM"] Laval, Quebec, Canada H7V 4A7
- --------------------------------------------------------------------------------
NEUROCHEM TO REPORT ON FIRST QUARTER OF NEW FISCAL YEAR
MONTREAL, Canada, May 10, 2004 -- NEUROCHEM INC. (NASDAQ: NRMX; TSX: NRM) --
today announced that on Tuesday, May 11, 2004, it will release its first quarter
2004 results for the period ended March 31, 2004.
The release of the results will be followed by a company-hosted teleconference
at 4:30 P.M. Eastern Daylight Time, May 11, 2004. During the teleconference,
Dr. Francesco Bellini, Chairman and Chief Executive Officer, and
Mr. Claude Michaud, Senior Vice-President, Finance and Chief Financial Officer,
will present the progress of the company over the first quarter as well as its
financial results.
To participate in the teleconference, please dial the following number
approximately 10 minutes prior to the start of the teleconference:
1 (800) 291-5032. A replay of the teleconference will be available for one week
(until May 18, 2004), commencing one hour after the end of the teleconference.
The instant replay number is 1 (800) 558-5253, code 21195095.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying, oral products addresses critical, unmet medical needs.
Fibrillex(TM), designated as an orphan drug and as a Fast Track Product
candidate, is in a Phase II/III clinical trial for the treatment of Amyloid A
Amyloidosis. Alzhemed(TM) and Cerebril(TM), for the treatment of Alzheimer's
Disease and for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid
Angiopathy, respectively, have both completed a Phase II clinical trial.
For additional information on Neurochem, please visit our website at:
(www.neurochem.com).
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation as well as other risks included in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance on the forward-looking statements included in
this news release.
These statements speak only as of the date made and Neurochem is under no
obligation and disavows any intention to update or revise such statements as a
result of any event, circumstances or otherwise.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dr. Lise Hebert
Vice President, Corporate Communications
lhebert@neurochem.com
Tel: (450) 680-4500
Fax: (450) 680-4501
NEUROCHEM INC.
275 Armand-Frappier
[LOGO "NEUROCHEM"] Laval (Quebec), Canada H7V 4A7
- --------------------------------------------------------------------------------
NEUROCHEM MOVES HEADQUARTERS
TO FORMER SHIRE BIOCHEM FACILITIES
MONTREAL, CANADA, MAY 10, 2004 -- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is
pleased to announce that it has moved all of its employees to its new
headquarters located in the state-of-the-art former Shire BioChem facilities.
The Company is now located in the Parc scientifique et de haute technologie de
Laval, Quebec, Canada.
The Company's new address and contact information is as follows:
NEUROCHEM INC.
275 ARMAND-FRAPPIER
LAVAL (QUEBEC)
CANADA
H7V 4A7
TEL.: (450) 680-4500
FAX: (450) 680-4501
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying, oral products addresses critical unmet medical needs.
Fibrillex(TM), designated as an orphan drug and as a Fast Track Product
candidate, is in a Phase II/III clinical trial for the treatment of AA
Amyloidosis. Alzhemed(TM) and Cerebril(TM) for the treatment of Alzheimer's
Disease and for the prevention of Hemorrhagic Stroke caused by cerebral amyloid
angiopathy respectively, have both completed a Phase II clinical trial.
For additional information on Neurochem, please visit our website at:
www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation as well as other risks included in public filings of
Neurochem. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. The reader
should not place undue reliance on the forward-looking statements included in
this news release. These statements speak only as of the date made and Neurochem
is under no obligation and disavows any intention to update or revise such
statements as a result of any event, circumstances or otherwise.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, Ph.D.
Vice President, Corporate Communications
lhebert@neurochem.com
Tel: (450) 680-4500
Fax: (450) 680-4501